Are entrepreneurial venture's innovation rates sensitive to investor complementary assets? Comparing biotech ventures backed by corporate and independent VCs

被引：136

作者：

Alvarez-Garrido, Elisa ^{[1
]}

Dushnitsky, Gary ^{[2
]}

机构：

[1] Georgia State Univ, Dept Managerial Sci, J Mack Robinson Coll Business, Atlanta, GA 30303 USA

[2] London Business Sch, Strategy & Entrepreneurship Area, London NW1 4SA, England

来源：

STRATEGIC MANAGEMENT JOURNAL | 2016年 / 37卷 / 05期

关键词：

entrepreneurial ventures; corporate venture capital; venture capital; patents; publications; innovation; RESEARCH-AND-DEVELOPMENT; COUNT DATA MODELS; KNOWLEDGE; PERFORMANCE; FIRMS; COMMERCIALIZATION; PATENT; PRODUCTIVITY; CAPITALISTS; NETWORKS;

D O I：

10.1002/smj.2359

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

Entrepreneurial ventures are a key source of innovation. Nowadays, ventures are backed by a wide array of investors whose complementary asset profiles differ significantly. We therefore assert that entrepreneurial ventures can no longer be studied as a homogeneous group. Rather, we harness the inherent dichotomy in the profiles of independent VCs and corporate investors to study ventures' innovation outcomes. Our sample consists of 545 U.S. biotechnology ventures founded between 1990 and 2003 and backed by independent venture capitalists (VCs) or corporate VCs (CVC). We find CVCs' investees exhibit higher rates of innovation output, compared to independent VC-backed peers. Moreover, the performance of CVC-backed ventures is sensitive to their ability to leverage corporate assets, underscoring the role of CVC accessibility and FDA approval requirements as the mechanisms associated with CVC contribution. Copyright (c) 2014 John Wiley & Sons, Ltd.

引用

页码：819 / 834

页数：16

共 76 条

[71] Estimating count data models with endogenous switching: Sample selection and endogenous treatment effects [J].